[1] 官方发布:新冠病毒被命名为SARS-CoV-2,疾病名称为COVID-19[J].中国医学计算机成像杂志,2020,26(1):38.
[2] WANG Q,ZHANG Y,WU L,et al.Structural and functional basis of SARS-CoV-2 entry by using human ACE2[J].Cell,2020,181(4):894-904.e9.
[3] WIDAGDO W,RAJ V S,SCHIPPER D,et al.Differential expression of the middle east respiratory syndrome coronavirus receptor in the upper respiratory tracts of humans and dromedary camels[J].J Virol,2016,90(9):4838-4842.
[4] PETROSILLO N,VICECONTE G,ERGONUL O,et al.COVID-19,SARS and MERS:are they closely related?[J].Clin Microbiol Infect,2020,26(6):729-734.
[5] CHU H,CHAN J F,WANG Y,et al.Comparative replication and immune activation profiles of SARS-CoV-2 and SARS-CoV in human lungs:an ex vivo study with implications for the pathogenesis of COVID-19[J].Clin Infect Dis,2020,71(6):1400-1409.
[6] COUTARD B,VALLE C,DE-LAMBALLERIE X,et al.The spike glycoprotein of the new coronavirus 2019-nCoV contains a furin-like cleavage site absent in CoV of the same clade[J].Antiviral Res,2020,176:104742.
[7] KORBER B,FISCHER W M,GNANAKARAN S,et al.Tracking changes in SARS-CoV-2 spike:evidence that D614G increases infectivity of the COVID-19 virus[J].Cell,2020,182(4):812-827.e19.
[8] PORMOHAMMAD A,GHORBANI S,KHATAMI A,et al.Comparison of confirmed COVID-19 with SARS and MERS cases-clinical characteristics,laboratory findings,radiographic signs and outcomes:a systematic review and meta-analysis[J].RevMed Virol,2020,30(4):e2112.
[9] 朱正保,郭道遐,郑小巍,等.严重急性呼吸综合征、中东呼吸综合征和新冠病毒肺炎特征比较[J].现代医学,2020,48(8):1087-1093.
[10] WAN S,XIANG Y,FANG W,et al.Clinical features and treatment of COVID-19 patients in northeast Chongqing[J].J Med Virol,2020,92(7):797-806.
[11] HAN R,HUANG L,JIANG H,et al.Early clinical and CT manifestations of coronavirus disease 2019(COVID-19) pneumonia[J].AJR Am J Roentgenol,2020,215(2):338-343.
[12] ZHENG F,TANG W,LI H,et al.Clinical characteristics of 161 cases of corona virus disease 2019(COVID-19) in Changsha[J].Eur Rev Med Pharmacol Sci,2020,24(6):3404-3410.
[13] 丁蓓,陶俞安.老年与中青年新型冠状病毒性肺炎患者的CT影像对比分析[J].现代医学,2020,48(8):995-999.
[14] MVLLER N L,OOI G C,KHONG P L,et al.Severe acute respiratory syndrome:radiographic and CT findings[J].AJR Am J Roentgenol,2003,181(1):3-8.
[15] ROCKX B,KUIKEN T,HERFST S,et al.Comparative pathogenesis of COVID-19,MERS,and SARS in a nonhuman primate model[J].Science,2020,368(6494):1012-1015.
[16] HUI D S C,ZUMLA A.Severe acute respiratory syndrome:historical,epidemiologic,and clinical features[J].Infect Dis ClinNorth Am,2019,33(4):869-889.
[17] CHONG Y P,SONG J Y,SEO Y B,et al.Antiviral treatment guidelines for middle east respiratory syndrome[J].InfectChemother,2015,47(3):212-222.
[18] QU R,LING Y,ZHANG Y H,et al.Platelet-to-lymphocyte ratio is associated with prognosis in patients with coronavirus disease-19[J].J Med Virol,2020,92(9):1533-1541.
[19] MUNSTER V J,FELDMANN F,WILLIAMSON B N,et al.Respiratory disease and virus shedding in rhesus macaques inoculated with SARS-CoV-2[J].bioRxiv.2020,3,001628.
[20] MCAULIFFE J,VOGEL L,ROBERTS A,et al.Replication of SARS coronavirus administered into the respiratory tract of African Green,rhesus and cynomolgus monkeys[J].Virology,2004,330(1):8-15.
[21] FALZARANO D,DE-WIT E,FELDMANN F,et al.Infection with MERS-CoV causes lethal pneumonia in the common marmoset[J].PLoS,2014,10(8):e1004250.
[22] SUN S H,CHEN Q,GU H J,et al.A mouse model of SARS-CoV-2 infection and pathogenesis[J].Cell HostMicrobe,2020,28(1):124-133.e4.
[23] LI K,WOHLFORD-LENANE C L,CHANNAPPANAVAR R,et al.Mouse-adapted MERS coronavirus causes lethal lung disease in human DPP4 knockin mice[J].Proc Natl Acad Sci U S A,2017,114(15):E3119-E3128.
[24] CHAN J F,ZHANG A J,YUAN S,et al.Simulation of the clinical and pathological manifestations of coronavirus disease 2019(COVID-19) in a golden syrian hamster model:implications for disease pathogenesis and transmissibility[J].Clin Infect Dis,2020,71(9):2428-2446.
[25] CHU Y K,ALI G D,JIA F,et al.The SARS-CoV ferret model in an infection-challenge study[J].Virology,2008,374(1):151-163.
[26] KIM Y I,KIM S G,KIM S M,et al.Infection and rapid transmission of SARS-CoV-2 in ferrets[J].Cell Host Microbe,2020,27(5):704-709.e2.
[27] DENG L,LI C,ZENG Q,et al.Arbidol combined with LPV/r versus LPV/r alone against Corona Virus Disease 2019:A retrospective cohort study[J].J infect,2020,81(1):e1-e5.
[28] CHAN K S,LAI S T,CHU C M,et al.Treatment of severe acute respiratory syndrome with lopinavir/ritonavir:a multicentre retrospective matched cohort study[J].Hong Kong Med J,2003,9(6):399-406.
[29] MCMAHON J H,UDY A,PELEG A Y.Remdesivir for the treatment of Covid-19-preliminary report[J].N Engl J Med,2020,383(10):992-993.
[30] SHEAHAN T P,SIMS A C,LEIST S R,et al.Comparative therapeutic efficacy of remdesivir and combination lopinavir,ritonavir,and interferon beta against MERS-CoV[J].Nat Commun,2020,11(1):222.
[31] NAGHIPOUR S,GHODOUSI M,RAHSEPAR S,et al.Repurposing of well-known medications as antivirals:hydroxychloroquine and chloroquine-from HIV-1 infection to COVID-19[J].Expert Rev Anti Infec Ther,2020,18(11):1119-1133.
[32] YAO X,YE F,ZHANG M,et al.In Vitro antiviral activity and projection of optimized dosing design of hydroxychloroquine for the treatment of Severe Acute Respiratory Syndrome Coronavirus 2(SARS-CoV-2)[J].Clin Infect Dis,2020,71(15):732-739.
[33] SINGH A K,MAJUMDAR S,SINGH R,et al.Role of corticosteroid in the management of COVID-19:a systemic review and a Clinician's perspective[J].DiabetesMetab Syndr,2020,14(5):971-978.
[34] KHALID I,ALRADDADI B M,DAIRI Y,et al.Acute management and long-term survival among subjects with severe Middle East Respiratory Syndrome Coronavirus Pneumonia and ARDS[J].Respir Care,2016,61(3):340-348.
[35] FELGENHAUER U,SCHOEN A,GAD H H,et al.Inhibition of SARS-CoV-2 by type I and type III interferons[J].J Biol Chem,2020,295(41):13958-13964.
[36] ZHOU Q,CHEN V,SHANNON C P,et al.Interferon-α2b treatment for COVID-19[J].Front Immunol,2020,11:1061.
[37] HUNG I F,LUNG K C,TSO E Y,et al.Triple combination of interferon beta-1b,lopinavir-ritonavir,and ribavirin in the treatment of patients admitted to hospital with COVID-19:an open-label,randomised,phase 2 trial[J].Lancet,2020,395(10238):1695-1704.
[38] DE-WILDE A H,RAJ V S,OUDSHOORN D,et al.MERS-coronavirus replication induces severe in vitro cytopathology and is strongly inhibited by cyclosporin A or interferon-α treatment[J].J Gen Virol,2013,94(Pt 8):1749-1760.
[39] RASHEED A M,FATAK D F,HASHIM H A,et al.The therapeutic potential of convalescent plasma therapy on treating critically-ill COVID-19 patients residing in respiratory care units in hospitals in Baghdad,Iraq[J].Infez Med,2020,28(3):357-366.
[40] 中华人民共和国国家卫生健康委员会.新型冠状病毒肺炎诊疗方案(试行第八版修订版)[J].中华临床感染病杂志,2021,14(2):81-88.
[41] TO K K,HUNG I F,IP J D,et al.Coronavirus Disease 2019(COVID-19) re-infection by a phylogenetically distinct severe acute respiratory syndrome coronavirus 2 strain confirmed by whole genome sequencing[J].Clin Infect dis,2021,73(9):e2946-e2951.
[42] 王法财,沈炳香,何春远,等.连花清瘟颗粒对新型冠状病毒肺炎的临床疗效及其机制的网络药理学研究[J].中药药理与临床,2020,36(2):93-101.
[43] TANG F,QUAN Y,XIN Z T,et al.Lack of peripheral memory B cell responses in recovered patients with severe acute respiratory syndrome:a six-year follow-up study[J].J Immunol,2011,186(12):7264-7268.
[44] ZHOU W,XU X,CHANG Z,et al.The dynamic changes of serum IgM and IgG against SARS-CoV-2 in patients with COVID-19[J].J Medical Virol,2021,93(2):924-933. |
